English 
Francês 
Alemão 
Italiano 
Japonês 
Norueguês 
Portuguese 
Spanish 
5 min of reading 
0 comments 
Technology Uses AI to Analyze Oocytes and Support Decisions in In Vitro Fertilization and Egg Freezing at Fertility Clinics.
Artificial intelligence is starting to change the way assisted reproduction clinics evaluate female fertility.
The technology, created by the Canadian company Future Fertility, analyzes microscopic images to identify patterns in oocyte quality and help doctors and patients make more informed decisions about reproductive treatments.
In Brazil, specialized clinics began using the innovation a little over a year ago. Today, around 50 units are already applying the system.
-
Casio Unveils Moflin, Robotic Pet With Artificial Intelligence Designed To Provide Emotional Comfort And Simulate A Permanent Affectionate Bond
-
Google Maps Revolutionizes GPS Navigation With Gemini Artificial Intelligence, Ask Maps Feature, and Advanced 3D Visualization for Route and Travel Planning
-
China Warns the U.S. of a “Terminator” Style Apocalypse: Military AI Rivalry, Sanctions Against American Startup, and Fear of Algorithms Deciding Who Lives or Dies Place the World on the Brink of a Nightmare That Seemed Like Fiction
-
Many Use It Every Day, but Few Know That ChatGPT Has Limitations in Brazil: Users Under 14 Need Authorization, Sensitive Data Should Not Be Entered, and Content May Be Monitored in Specific Cases
The tool offers a more detailed and personalized analysis of women’s reproductive potential — something that, until recently, doctors estimated mainly based on the patient’s age.
This new approach comes at a time when many women choose to delay motherhood for professional, personal, or financial reasons.
In this scenario, tools capable of providing more accurate information about fertility are becoming increasingly important.
How Artificial Intelligence Analyzes Oocyte Quality
Historically, doctors face difficulties in assessing oocyte quality.
Unlike embryos or sperm, these gametes have characteristics that are hard to measure with just microscopic observation.
Thus, artificial intelligence helps overcome this challenge by processing large volumes of data and identifying patterns that the human eye cannot perceive.
“Artificial intelligence analyzes microscopic images of oocytes with a level of detail that exceeds human observational capacity,” explains Alex Krivoi, Chief Technology Officer and co-founder of the company.
According to him, developers trained the algorithms with a database that includes over 650,000 images of oocytes linked to real clinical outcomes.
With this information, the system estimates the likelihood of an oocyte developing to the blastocyst stage — the phase at which the embryo can be transferred to the uterus in an in vitro fertilization treatment.
“In simple terms, AI transforms visual information from the oocyte into data that helps doctors and embryologists better understand its developmental potential and how this can influence the outcomes of fertility treatment,” says Krivoi.
Technology for Egg Freezing and In Vitro Fertilization
The company’s platform includes tools aimed at different stages of reproductive planning.
One of them is the system VIOLET™, which supports egg freezing cycles — a procedure increasingly sought by women wanting to preserve fertility.
“At the same time, more and more women are choosing to delay pregnancy for personal, professional, or financial reasons, which increases the importance of more precise information about fertility.
By bringing our AI-based oocyte evaluation tools, including VIOLET™ for egg freezing and MAGENTA™ for in vitro fertilization (IVF) treatments, to Brazil.
Clinics can offer patients a more personalized view of their reproductive potential, rather than relying solely on population averages, such as age,” says Rafael González, Global Head of Sales & Commercial Strategy of the company.
Another solution, called MAGENTA™, assists doctors during in vitro fertilization treatments by providing detailed analyses of each oocyte’s quality.
Individual Assessment of Oocyte Quality
One of the key advances of the technology is the ability to analyze each oocyte individually — something that previously represented a significant challenge.
“Traditionally, doctors infer oocyte quality indirectly, mainly based on the patient’s age.
While age serves as a useful starting point, it reflects population trends and does not capture the variability among individual oocytes,” explains Dr. Dan Nayot, Chief Medical Officer and co-founder of the company.
According to him, artificial intelligence adds a new layer of data to the clinical process.
“AI-based assessments, like MAGENTA™ and VIOLET™, introduce a new layer of objective information.
By analyzing microscopic images of individual oocytes, AI identifies subtle visual patterns associated with developmental potential.
In practice, this allows clinics to evaluate each oocyte individually, supporting clearer counseling for patients, better expectation management, and more informed treatment decisions.”
Clinical validation studies show that the models used by the company achieve 28% more predictive accuracy compared to traditional assessments performed by specialists.
Infertility Rises and Drives the Search for New Technologies
The advancement of these technologies occurs in a context of growing concern about fertility worldwide.
Studies indicate that one in six people faces difficulties in becoming pregnant.
In Brazil, the Brazilian Society of Assisted Reproduction estimates that around eight million people live with infertility.
Even with advancements in reproductive medicine, between 60% and 70% of in vitro fertilization cycles still do not result in pregnancy.
A UN survey published in 2025, named the True Fertility Crisis, analyzed data from 14 countries and identified significant changes in birth patterns.
The study revealed that about 20% of adults of reproductive age believe they will not be able to have the number of children they desire.
In this context, better understanding oocyte quality becomes an essential factor in increasing reproductive success chances.
Fertility Technology is Already Present in Brazilian Clinics
Currently, more than 300 clinics in over 35 countries use Future Fertility’s technology. In Brazil, dozens of assisted reproduction centers have already incorporated the system into their routines.
“Future Fertility’s AI-based oocyte evaluation tools are already present in more than 50 fertility clinics in Brazil.
MAGENTA™ and VIOLET™ integrate into the workflow of laboratories, where professionals analyze images of the oocytes and generate quality reports,” explains Christy Prada, CEO of the company.
According to her, these reports assist doctors and patients during reproductive counseling and contribute to more informed decisions.
The Future of Female Fertility with Artificial Intelligence
Experts believe that artificial intelligence can profoundly transform assisted reproduction.
By allowing more detailed analyses of oocyte quality, the technology paves the way for more personalized treatments.
This can increase the chances of success in procedures such as in vitro fertilization and help women better plan egg freezing.
The combination of reproductive medicine and digital technology may mark a new chapter in how doctors and patients understand and treat female fertility.
Learn more at: AI and Motherhood: The Machine Learning Revolution in Oocyte Assessment
Seja o primeiro a reagir!